{"id":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","name":"MMI CMS","timestamp":1446799444935,"order":["84067e7e-f276-9580-7fb4-4079ed20b57c","8da11c82-f2d3-1081-a03c-4652cf514e26","5b76a55a-c1d5-b503-ce9d-e742a3335189","72875180-2482-5248-14fb-bc7d317b18b5","006a5dc2-5579-e9c9-81e1-94ffe34de213","33e92355-7ace-223c-3f91-ffb988fa7dc6","8f8e871f-b0d0-fe8c-d8cc-35af26d78927","d54c8959-94ec-ab31-1e06-b9ad1e98e865","d9505bb0-c169-ea57-b097-6b5aed41d576","c07cae82-bcd0-3162-380e-f79a8f974100"],"requests":[{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"006a5dc2-5579-e9c9-81e1-94ffe34de213","name":"POST Document : 201 Created","description":"We are expecting the REST 201 \"CREATED\" STANDARD HTTP code.","url":"http://localhost:8080/dms/rest/documents","method":"POST","headers":"Accept: application/json\n","data":[{"key":"title","value":"Title Goes here","type":"text"},{"key":"products","value":"Temodal®, MSD Sharp & Dohme GmbH|TEMOZO-cell, cell pharm GmbH|Temozolomid HEXAL, Hexal AG|Temozolomid Hospira, Hospira Deutschland GmbH|Temozolomid-ratiopharm, ratiopharm GmbH|Temozolomid ribosepharm, Hikma Pharma GmbH|Temozolomid TEVA, TEVA GmbH|Temomedac, medac GmbH","type":"text"},{"key":"ingredients","value":"ing1|ing2|ing3","type":"text"},{"key":"companies","value":"MSD Sharp & Dohme GmbH|cell pharm GmbH|Hexal AG","type":"text"},{"key":"articledate","value":"06.11.2015","type":"text"},{"key":"description","value":"Die Hersteller Temozolomid-haltiger Arzneimittel  informieren in diesem Rote-Hand-Briefüber Fälle von Leberschäden, einschließlich letalem Leberversagen bei Patienten, die mit Temozolomid behandelt wurden. Deshalb  gelten ab sofort spezielle Empfehlungen zur Überwachung der Leberfunktion: -Die Leberwerte sollen vor der Behandlung und nach jedem Behandlungszyklus bestimmt werden. -Bei Patienten mit einem 42-tägigen Zyklus sollen die Werte auch in der Mitte des Behandlungszyklus bestimmt werden. -Bei abnormen Leberwerten ist das Nutzen-Risiko-Verhältnis vor und während der Behandlung sorgfältig abzuwägen und ggf. nicht begonnen oder abgebrochen werden.","type":"text"},{"key":"originalfile","value":"Rote-Hand-Brief zu Temozolomid.pdf","type":"text"},{"key":"sources","value":"Rote Hande Magazine|AWFS Magazine|Hexal AG","type":"text"},{"key":"friendlyurl","value":"http://www.gelbe-liste.de/c/document_library/get_file?uuid=319cf68f-6ebd-4c47-b533-f1786cc029b3&groupId=84530","type":"text"},{"key":"htmltitel","value":"not known html title","type":"text"},{"key":"keywords","value":"Rote Hande|Temozolomid|Hexal","type":"text"},{"key":"rights","value":"all","type":"text"}],"dataMode":"urlencoded","timestamp":0,"version":2,"time":1447243077691},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"33e92355-7ace-223c-3f91-ffb988fa7dc6","name":"POST Document : 400 Bad Request","description":"No title will trigger bad request.","url":"http://localhost:8080/cms/documents/articles","method":"POST","headers":"","data":[{"key":"title","value":"","type":"text"},{"key":"products","value":"Temodal®, MSD Sharp & Dohme GmbH|TEMOZO-cell, cell pharm GmbH|Temozolomid HEXAL, Hexal AG|Temozolomid Hospira, Hospira Deutschland GmbH|Temozolomid-ratiopharm, ratiopharm GmbH|Temozolomid ribosepharm, Hikma Pharma GmbH|Temozolomid TEVA, TEVA GmbH|Temomedac, medac GmbH","type":"text"},{"key":"ingredients","value":"ing1|ing2|ing3","type":"text"},{"key":"companies","value":"MSD Sharp & Dohme GmbH|cell pharm GmbH|Hexal AG","type":"text"},{"key":"articledate","value":"06.11.2015","type":"text"},{"key":"description","value":"Die Hersteller Temozolomid-haltiger Arzneimittel  informieren in diesem Rote-Hand-Briefüber Fälle von Leberschäden, einschließlich letalem Leberversagen bei Patienten, die mit Temozolomid behandelt wurden. Deshalb  gelten ab sofort spezielle Empfehlungen zur Überwachung der Leberfunktion: -Die Leberwerte sollen vor der Behandlung und nach jedem Behandlungszyklus bestimmt werden. -Bei Patienten mit einem 42-tägigen Zyklus sollen die Werte auch in der Mitte des Behandlungszyklus bestimmt werden. -Bei abnormen Leberwerten ist das Nutzen-Risiko-Verhältnis vor und während der Behandlung sorgfältig abzuwägen und ggf. nicht begonnen oder abgebrochen werden.","type":"text"},{"key":"originalfile","value":"Rote-Hand-Brief zu Temozolomid.pdf","type":"text"},{"key":"sources","value":"Rote Hande Magazine|AWFS Magazine|Hexal AG","type":"text"},{"key":"friendlyurl","value":"http://www.gelbe-liste.de/c/document_library/get_file?uuid=319cf68f-6ebd-4c47-b533-f1786cc029b3&groupId=84530","type":"text"},{"key":"htmltitel","value":"not known html title","type":"text"},{"key":"keywords","value":"Rote Hande|Temozolomid|Hexal","type":"text"},{"key":"rights","value":"all","type":"text"}],"dataMode":"urlencoded","timestamp":0,"version":2,"time":1446805548246},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"5b76a55a-c1d5-b503-ce9d-e742a3335189","name":"updateArticle : 200 OK","description":"","url":"http://localhost:8080/dms/rest/articles/456","method":"PUT","headers":"Accept: application/json\nContent-Type: application/json\n","data":"{\n    \"authors\": [],\n    \"bodyPictures\": [],\n    \"friendlyUrl\": \"http://localhost:8080/dms/rest/articles/456\",\n    \"htmlTitle\": \"Article Two NOW updated\",\n    \"relations\": [],\n    \"rights\": [],\n    \"searchable\": false,\n    \"version\": 0\n}","dataMode":"raw","timestamp":0,"version":2,"time":1447324018063},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"72875180-2482-5248-14fb-bc7d317b18b5","name":"GetDocument : JSON","description":"","url":"http://localhost:8080/dms/rest/documents/456","method":"GET","headers":"Accept: application/json\n","data":[],"dataMode":"params","timestamp":0,"version":2,"time":1447231007133},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"84067e7e-f276-9580-7fb4-4079ed20b57c","name":"Get Articles","description":"","url":"http://localhost:8080/dms/rest/articles?offset=30&limit=15","method":"GET","headers":"Accept: application/json\n","data":"{\n    \"created\": \"2015-11-11T12:57:25.733+01:00\",\n    \"id\": 45576,\n    \"name\": \"New Title for 456: at 13:01\"\n}","dataMode":"raw","timestamp":0,"version":2,"time":1447316035329},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"8da11c82-f2d3-1081-a03c-4652cf514e26","name":"GetArticle : JSON","description":"","url":"http://localhost:8080/dms/rest/articles/456","method":"GET","headers":"Accept: application/json\n","data":"{\n    \"created\": \"2015-11-11T12:57:25.733+01:00\",\n    \"id\": 45576,\n    \"name\": \"New Title for 456: at 13:01\"\n}","dataMode":"raw","timestamp":0,"version":2,"time":1447316572232},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"8f8e871f-b0d0-fe8c-d8cc-35af26d78927","name":"deleteDocument : 202 Accepted","description":"","url":"http://localhost:8080/dms/rest/documents/456","method":"DELETE","headers":"Accept: application/json\n","data":"","dataMode":"raw","timestamp":0,"version":2,"time":1447245081805},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"c07cae82-bcd0-3162-380e-f79a8f974100","name":"Get Documents","description":"","url":"http://localhost:8080/dms/rest/documents?offset=30&limit=15","method":"GET","headers":"Accept: application/json\n","data":"{\n    \"created\": \"2015-11-11T12:57:25.733+01:00\",\n    \"id\": 45576,\n    \"name\": \"New Title for 456: at 13:01\"\n}","dataMode":"raw","timestamp":0,"responses":[],"version":2},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"d54c8959-94ec-ab31-1e06-b9ad1e98e865","name":"getDocument : 500 DataNotFoundException","description":"","url":"http://localhost:8080/dms/rest/documents/4561","method":"GET","headers":"Accept: application/json\n","data":"","dataMode":"raw","timestamp":0,"responses":[],"version":2},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"d9505bb0-c169-ea57-b097-6b5aed41d576","name":"updateDocument : 200 OK","description":"","url":"http://localhost:8080/dms/rest/documents/456","method":"PUT","headers":"Accept: application/json\nContent-Type: application/json\n","data":"{\n    \"created\": \"2015-11-11T12:57:25.733+01:00\",\n    \"id\": 45576,\n    \"name\": \"New Title for 456: at 13:01\"\n}","dataMode":"raw","timestamp":0,"version":2,"time":1447244370707}]}